Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported that the FDA has granted final approval for the company's abbreviated new drug application to market its generic version of Merck's osteoporosis treatment Fosamax tablets, 5mg, 10mg, 35mg, 40mg and 70mg.
Subscribe to our email newsletter
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. Shipment of the product will begin immediately.